DENVER, CO / ACCESSWIRE / November 23, 2020 / Solitario Zinc Corp. ("Solitario") (NYSE American:XPL) (TSX:SLR) is pleased to announce that it is participating in the H.C. Wainwright & Co. Virtual Mining Conference, November 30th through December 1st. President and CEO, Chris Herald will host one on one meetings during the event and will deliver an online presentation and corporate update on Monday, November 30th at 2:00pm EST. View webcast and replay here. For more information on the H.C Wainwright Virtual Mining Conference please visit https://hcwevents.com/mining/.

About Solitario

Solitario is a well-funded emerging zinc exploration and development company traded on the NYSE American ("XPL") and on the Toronto Stock Exchange ("SLR"). Solitario holds 50% joint venture interest (Teck Resources 50%) in the high-grade, open-pittable Lik zinc deposit in Alaska and a 39% joint venture interest (Nexa Resources holds the remaining 61% interest) on the high-grade Florida Canyon zinc project in Peru. Solitario also holds a 9.9% equity interest in Vendetta Mining. Solitario's Management and Directors hold approximately 9.3% (excluding options) of the Company's 58.1 million shares outstanding. Solitario's cash balance and marketable securities stand at approximately US$8.0 million. Additional information about Solitario is available online at www.solitariozinc.com.

FOR MORE INFORMATION, CONTACT:

Christopher E. Herald
President & CEO
(303) 534-1030, Ext. 14

Valerie Kimball
Director – Investor Relations
720-933-1150
(800) 229-6827

SOURCE: Solitario Zinc Corp.

ReleaseID: 617785

TORONTO, ON / ACCESSWIRE / November 23, 2020 / Sparta Group (TSXV:SAY) (the "Corporation" the "Company", "Sparta Group", "Sparta Capital" or "Sparta") is well positioned to help electronics manufacturers and importers deal with new Ontario government recycling regulations slated to take effect January 2021. In fact, the environment-focused company is one of only a few organizations that are approved to do so.

Sparta's e-waste recycling division, ReECO Tech Electronic Conversions/ERS-International ("ReECO Tech/ERS-International") is known for its responsible electronic recycling and upcycling abilities, as well as its asset remarketing and recovery services. Organizations around the world trust the electronics recycling operation, especially in light of its efficient processes and security measures.

The Ontario government recently introduced new regulations requiring all electronic manufacturers/producers to collect and safely manage the full life cycle of their electronic equipment, such as cell phones, computers, and printers. Under the regulation, which will be enforced as of January 1, 2021, producers are encouraged to reuse and refurbish products so they can be resold. The Resource Productivity and Recovery Authority ("RPRA") will be in charge of enforcing the new regulation. This includes monitoring the performance of producers to make sure they are in compliance.

"We are 100 percent confident that we have the right systems in place to help many more electronics companies ensure compliance under these new rules. We have an efficient materials tracking system in place that is powered by our proprietary data-base management platform as well as high security, strict operations standards, sophisticated asset tracking, and a zero-waste policy. Nothing gets tossed out at our facility and we have a strong capability of upcycling waste into new, valuable products, due to our ongoing materials analytics, carried out in our on-site laboratory research facilities. This is why we've been approved by the governing authority, RPRA; a distinction that few have been able to attain," said President and Chief Technology Officer for Sparta Group, John O'Bireck.

Those who don't comply under the new Ontario government regulations could face hefty fines as the province steps up its push for developing a circular economy. The government has stated that electronics manufacturers and importers could save millions by transitioning from current waste diversion programs to a full producer responsibility model.

Sparta's e-waste recycling division can arrange for haulage, collection, certified destruction, as well as the remarketing of electronics. Furthermore, working with ReECO Tech/ERS-International means the responsibility of a manufacturer or importer's reporting mandate to the government will be handled on behalf of the producer. If a manufacturer falls short of its quota, ReECO Tech/ERS-International can ensure that the producer doesn't get penalized as they can transfer credits through the e-waste facility's other partners.

"We know the pitfalls of reactive response to the kind of regulation that is about to go into effect. However, we can help manufacturers be proactive by getting them ready now to meet this important upcoming government mandated obligation. All they have to do is reach out to us and we can get them started so as to avoid any penalties for non-compliance," said Alfea Principe, Director of Global Compliance for ReECO Tech Electronic Conversions Ltd.

About Sparta™

Sparta Group (a.k.a. Sparta Capital Ltd.) is a technology-based company that owns or holds a controlling interest in a network of independent businesses that supply energy saving technologies designed to reduce energy inefficiencies, achieve reduced emissions and increase operating efficiencies in various industries. In response to the COVID-19 crisis, Sparta has also expanded its scope to help facilitate supply of necessary materials while assisting talented inventors who are looking to introduce innovative technical solutions that will bring greater normalcy to the post COVID-19 world. Sparta's network of independent businesses provides a wide range of specialized energy capturing, converting, optimizing, and related services to the commercial sector. Sparta provides capital, technical and engineering expertise, legal support, financial and accounting knowledge, strategic planning and other shared services to its independent businesses.

Sparta is a publicly traded company listed on the TSX Venture Exchange Inc. under the symbol "SAY" (TSX.V: SAY). Additional information is available at www.spartagroup.ca or on SEDAR at www.sedar.com.

For further information please contact:

John O'Bireck, President & CTO
Email: jobireck@spartagroup.ca
Telephone: (905) 751-8004

Cautionary Statements:

This news release contains "forward-looking information" within the meaning of applicable securities laws. When used in this news release, the words "estimate", "project", "belief", "anticipate", "intend", "expect", "plan", "predict", "may" or "should" and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information. Although the Corporation believes in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate that the expectations reflected in this forward-looking information are reasonable, readers are cautioned to not place undue reliance on forward-looking information because the Corporation can give no assurance that they will prove to be correct. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date of publication of this news release and the Corporation undertakes no obligation to update such forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Furthermore, the Corporation undertakes no obligation to comment on analyses, expectations or statements made by third parties in respect of the Corporation. These include, but are not limited to, the failure to obtain necessary regulatory approvals, necessary financing and risks associated with the environmental technologies industry in general. All forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Sparta Capital Ltd.

ReleaseID: 617935

RENO, NV / ACCESSWIRE / November 23, 2020 / GoooGreen, Inc. (OTC PINK:GOOO) subsidiary VegasWINNERS Inc., which provides sports betting enthusiasts with high-quality analysis, research, data, guidance and professional advice, announced today that record-setting, fifteen-time World Series of Poker champion Phil Hellmuth has joined the company's advisory board.

VegasWINNERS business model is built to capitalize on and support the continued growth of the online gaming industry. As more states legalize sports gambling, VegasWINNERS is in the process of expanding its team of renowned sports handicappers and advisory board members that include recognizable industry leaders and creative thinkers like Phil Hellmuth.

Wayne Allyn Root, CEO of VegasWINNERS stated, "Phil remains the gold standard in the world of high-stakes poker and gambling and continues to be at the top of his game. As the all-time WSOP bracelet winner, he brings that competitive spirit to VegasWinners."

Phil Hellmuth, VegasWINNERS newly appointed Advisory Board Member stated "I'm a legend in the Poker World. I'm in the Hall of Fame. Wayne Allyn Root is a legend in the sports gambling world. Wayne has a star on the Las Vegas Walk of Stars. Great minds think alike. I think 2 visionaries of gambling can achieve great things together."

Wagering on sports, including but not limited to the NFL, NBA, NHL, MLB, UFC, PGA, Soccer and NASCAR, as well as college sports (primarily football and basketball) are national pastimes for millions of sports enthusiasts. Historically, betting on sports was only legal in the State of Nevada and/or bets between friends, and those willing to bet illegally. In 2018, the United States Supreme Court decision allowing states to legalize sports betting has changed everything, creating tremendous opportunity. Twenty-two states plus Washington DC. have already legalized wagering on sports and, all but five states have legislation pending to allow it.

ABOUT PHIL HELLMUTH
Phil Hellmuth, Jr. is universally regarded as the best poker player in the world. Hellmuth has an unprecedented 15 World Championships of Poker (15 WSOP); no one else has over 10. Hellmuth considers himself a force for good and wrote the book: #POSITIVTY You Are Always In The Right Place At The Right Time. #POSITIVTY (only available on Amazon) gives the world "8 Life Tips" and is heavily endorsed by Tony Robbins and Sheryl Sandberg. Hellmuth holds the world record for both most cash finishes at the WSOP (140) and most WSOP final tables (57) and 11 second place finishes. Of his 57 final tables, 20 are in non Hold'em games. Of those 20 non Hold'em events, Hellmuth has finished runner-up five times. His live tournament winnings exceed $23,000,000. He won the WSOP championships in 1989, 1992, 1993 (3), 1997, 2001, 2003 (2), 2006, 2007, 2012 (2), 2015, 2018. For further information please see https://philhellmuth.com/

ABOUT GOOOGREEN, INC.
GoooGreen, Inc., through its subsidiary VegasWinners, Inc., is engaged in the business of sports gambling research, data, advice, analysis and predictions utilizing all available media, advertising formats and its database of users. Revenues are expected to accelerate due to the explosion of sports handicapping arising from the 2018 Supreme Court decision that States have the right to approve sports gambling and the resulting State by State rapid approval of sports gambling. For further information, please see https://vegaswinners.com/.

SAFE HARBOR STATEMENT
This press release contains forward-looking statements that can be identified by terminology such as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

MEDIA CONTACT:
Mario Flores
Sportivo
323-314-1818
mario.flores@sportivo.us

SOURCE: GoooGreen Inc.

ReleaseID: 617801

TORONTO, ON / ACCESSWIRE / November 23, 2020 / Perimeter Medical Imaging AI, Inc. (TSXV:PINK)(FSE:4PC) ("Perimeter" or the "Company"), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need, today reported financial results for its third quarter ending September 30, 2020 and provided an update on its operations.

Jeremy Sobotta, Perimeter's Chief Executive Officer, stated, "Bolstered by a strong balance sheet, we continue to make good progress executing against our clinical development and commercialization plans. We remain committed to bringing our novel medical imaging technology to market, with the goal of creating better long-term outcomes for patients and lower costs to the healthcare system. In addition, with the support of grant funding received from the Cancer Prevention and Research Institute of Texas (CPRIT), we are advancing artificial intelligence and machine learning tools through clinical development."

Corporate Highlights

Perimeter was recognized as one of the "10 Most Promising Companies" at the 2020 Texas Life Science Forum co-hosted by the Rice Alliance for Technology and Entrepreneurship and BioHouston.
Backed by a CPRIT grant, Perimeter continues to advance its ATLAS AI Project with installations of its proprietary, ultra-high resolution imaging platform at leading cancer center sites in Texas, including University of Texas MD Anderson Cancer Center, Baylor College of Medicine, and UT Health San Antonio. The first stage of the project, which is currently underway, will collect images of breast tumors from up to 400 patients for the purpose of training and testing Perimeter's "ImgAssist" AI technology.

Summary of Third Quarter 2020 Results

All of the amounts are expressed in Canadian dollars unless otherwise indicated and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS") applicable to the preparation of interim financial statements, including International Accounting Standard ("IAS") 34, Interim Financial Reporting.

Operating expenses for the three months ended September 30, 2020 were $2,201,256 compared to $2,323,233 during the same period in 2019.

The net income for the three months ended September 30, 2020 was $800,030 compared to a $(1,843,303) loss in the same period in 2019.

For the nine-month period ended September 30, 2020, cash used in operating activities was $5,617,948.

As at September 30, 2020, cash and cash equivalents were $9,065,685 and investments were $2,930,660.

As of September 30, 2020, the Company received US$1,220,666 of the US$7,446,844 available from the CPRIT grant to fund activities related to the first year of its ATLAS AI Project.

As at September 30, 2020, Perimeter had 38,866,728 common shares issued and outstanding and 9,039,775 warrants outstanding with a weighted-average exercise price of $1.55. Of those warrants, 3,446,696 with an exercise price of $2.00 are subject to accelerated conversion if the common shares of the Company trade above a $3.00 15-day volume-weighted average price on the TSX Venture Exchange.

For detailed third quarter financial results, please see Perimeter's filings at www.sedar.com and on the company's website at https://ir.perimetermed.com/.

About Perimeter Medical Imaging AI, Inc.

Perimeter Medical Imaging AI (TSXV:PINK; FSE:4PC) is a Toronto-based company with U.S. headquarters in Dallas, Texas that is developing, with plans to commercialize, advanced imaging tools that allow surgeons, radiologists, and pathologists to visualize microscopic tissue structures during a clinical procedure. Perimeter's OTIS™ platform is a point-of-care imaging system that provides clinicians with real-time, ultra-high-resolution, sub-surface image volumes of the margin (1-2 mm below the surface) of an excised tissue specimen. The ability to visualize microscopic tissue structures during a clinical procedure in addition to standard of care tissue assessment for decision making during the procedure has the potential to result in better long-term outcomes for patients and lower costs to the healthcare system. Perimeter's OTIS™ platform is cleared by the FDA as an imaging tool in the evaluation of excised human tissue microstructure by providing two-dimensional, cross-sectional, real-time depth visualization, with image review manipulation software for identifying and annotating regions of interest. In addition, Perimeter is developing advanced artificial intelligence/machine learning image assessment tools intended to increase the efficiency of review.

Perimeter's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month by the Canadian Cancer Society and the American Cancer Society, driving home the company's dedication to helping surgeons, radiologists and pathologists use Perimeter's imaging technology and AI (Artificial Intelligence) in the fight against breast cancer, which is estimated to account for 30% of all female cancer diagnoses this year.

CONTACT:

Jodi Regts
Corporate Communications / Investor Relations
Perimeter Medical Imaging AI, Inc.
+1 778-999-5634
media@perimetermed.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains statements that may constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may", "would", "could", "will", "likely", "believe", "expect", "anticipate", "intend", "plan", "estimate" and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management's future outlook and anticipated events or results, and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, financial results, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, information regarding the planned development of Perimeter's ATLAS AI Project; available funding under the CPRIT grant; and research and development activities are forward-looking information.

Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described the joint information circular dated May 12, 2020, prepared in respect of the securityholder meetings held on June 17, 2020 a copy of which is available on Perimeter's SEDAR profile at www.sedar.com, and could cause actual events or results to differ materially from those projected in any forward-looking statements. In particular, we note the risk that our technology may not achieve the anticipated benefits in terms of surgical outcomes. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws.

SOURCE: Perimeter Medical Imaging

ReleaseID: 617897

TORONTO, ON / ACCESSWIRE / November 23, 2020 / Roscan Gold Corporation ("Roscan" or the "Company") (TSX-V:ROS)(FSE:2OJ)(OTC PINK:RCGCF) is pleased to announce positive diamond drill results (Figure 1) from an additional 16 holes totaling 3,241 meters (m) at its Southern Mankouke Discovery. DDMan-20-79 (Figure 1 and Figure 2) intersected 5.35 gpt over 53m from 126.5m, including 12.5 gpt over 12m. Additionally, hole DDMan-20-77 intersected 3.99 gpt over 17m from 166.3m in Fresh Rock (Figure 3).

This very important discovery at Southern Mankouke has a strong magnetic signature and we plan to conduct a detailed interpretation of the recently completed air borne geophysical survey to assist in further drilling. Additional drilling will be required to further outline this strong hydrothermal system now with the confidence in the existence of a "root" source. The "structural corridor" in this area has become more evident as we continue drilling.

Drilling has intercepted un-oxidized material in at least seven holes (DDMan20-25, 41,52,54,61, and 77) in 2020. These fresh rock-sulphide intercepts clearly demonstrate an association of gold with disseminated pyrite, minor arsenopyrite and hydrothermal alteration which includes sericite-silica- dolomite/ankerite-albite-magnetite and quartz veining (mainly veinlets). The style of alteration encountered is typical of other gold deposits found in the region including Sadiola, Loulo Deposits and Fekola.

Drilling Highlights:

Southern Mankouke – Diamond Drill Holes

5.35 gpt gold over 53m from drill hole DDMAN20-79 from 126.5m

Including 7.78 gpt gold over 5m from 128.5m
And 12.5 gpt gold over 12m from 157.5m

And 2.52 gpt gold over 47m from drill hole DDMAN20-79 from 45.5m

Including 10.3 gpt gold over 6m from 72.5m

2.84 gpt gold over 40m from drill hole DDMAN20-70 from 114.5m

Including 6.23 gpt gold over 4m from 121.5m
And 7.06 gpt gold over 8m from 144.5m

13.9 gpt gold over 6m from drill hole DDMAN20-81 from 53.5m

Including 36.7 gpt gold over 2m from 56.5m

3.99 gpt gold over 17m from drill hole DDMAN20-77 from 166.3m

Including 8.43 gpt gold over 4m from 168.3m

And 2.40 gpt gold over 18m from drill hole DDMAN20-77 from 80.5m

Including 9.60 gpt gold over 2m from 83.5m

3.52 gpt gold over 12m from drill hole DDMAN20-72 from 112.5m

Including 9.94 gpt gold over 3m from 116.5m

34.0 gpt gold over 1m from drill hole DDMAN20-76 from 135.5m

1.97 gpt gold over 11m from drill hole DDMAN20-64 from 61.5m

Including 7.83 gpt gold over 2m from 70.5m

3.34 gpt gold over 6m from drill hole DDMAN20-69 from 57.5m

Including 16.3 gpt gold over 1m from 62.5m

Notes: 1: True width yet to be determined, 2: Table 1 – Assay Highlights, 3: 0.5gpt used as cut-off with 4m internal dilution for drill holes, and 2m internal dilution for regional drill holes, 4: No top-cut.

Nana Sangmuah, President and CEO, stated, "These positive results further confirm the continuity of the mineralization at Southern Mankouke and we are pleased to have encountered more fresh rock in both old and new intercepts. We remain confident that the feed source of the hydrothermal alterations should culminate in tracing a big system analogous to some of the known large deposits in the region with similar lithological controls.

We remain focused on testing the full potential of our tenement package in order to yield more discoveries and expand on the success at Southern Mankouke (Figure 2). Drilling in 2020 continues to unlock the potential of our highly prospective land package which should lead to more news flow in the coming weeks."

Figure 1: Plan View of the Southern Mankouke Drilling

Figure 2: Longitudinal View Depicting Depth and High-Grade Continuity

|
Figure 3: Cross Section Depicting the Extension to Vertical Depth – DDMan-20-77

Drill hole DDMan-20-79 intersected one of the highest gram meters to date at Southern Mankouke. This drill hole, when coupled with previously high-grade drill holes, shows the persistent high-grade nature of the deposit. It should be noted that this hole is within the current drill area and drilled at a different azimuth of 340 as shown in the drilling plan.

Drill hole DDMan-20-77 intersected fresh rock over an interval of 17m with high-grade gold of 3.99gpt. This hole identifies the potential of the deposit in fresh rock and drilling will continue to clearly understand the extent of the mineralization.

Drilling will continue on the Mankouke South West (offset) area as soon as access allows, and a second drill can be moved in. Future drilling to test this area will be assisted by the air borne survey.

Figure 4: Geophysics data showing the major structure on Kandiole Project

The structural corridor is very evident with this round of drilling and many cross cutting faults occur which indicates the extension of the mineralization. Our Technical Team has now embarked on detailed exercise of logging and re-logging of all the previous cores to better understand the deposit. It is noted that this exercise has now shown that we are intersecting more fresh rock in earlier drilling than anticipated which is very encouraging.

Geology

The gold mineralization at Mankouke South is located approximately 25km east of the Fekola mine (B2Gold Corp.). Gold mineralization in Mankouke South occurs within hydrothermally altered and sheared metasediments of the Kofi formation which include greywacke, limestone and diamictite.

Drilling has intercepted unoxidized material in at least seven holes (DDMan20-25, 41,52,54,61, and 77). These fresh rock-sulphide intercepts clearly demonstrate an association of gold with disseminated pyrite, minor arsenopyrite and hydrothermal alteration which includes sericite-silica-dolomite/ ankerite-albite-magnetite and quartz veining (mainly veinlets). The style of alteration encountered is typical of other gold deposits found in the region including Sadiola, Loulo deposits and Fekola.

The Mankouke South deposit is located within the sheared eastern limb of a fold within hydrothermally altered greywacke-diamictite-carbonate rocks directly above a footwall unit of finely banded and alternating graphitic shale and limestone referred to as the dirty limestone ("DLS"). The DLS unit is easily recognizable in the core and does not, to date, host any gold but forms a distinct footwall marker to the mineralization. The Mankouke South mineralization clearly occurs in the rock package above the DLS and has been enriched, upgraded, and concentrated by subsequent folding and shearing of the fold limbs. This deposit is therefore structurally controlled. The setting appears to be analogous to the Sadiola orebodies mined by IAMGOLD, in particular the FE open pit deposits.

Figure 5: Drill Core Photo DDMan-20-79 showing high-grade sections mineralization style of deposit

Figure 6: Drill Core Photo DDMan-20-77 showing broadly high-grade sections in Fresh Rock

Drilling Contract and Analytical Protocol

The drilling contracts were awarded to Target Drilling SARL and Geodrill who both employ multi-purpose (AC/RC/DD) rig and AC rigs at the Kandiole Project. The AC drilling is mainly focused on drilling exploration targets. Roscan applied industry-standard QA/QC procedures to the program. Certified reference materials, blanks and field duplicates are inserted at appropriate intervals.

The samples are sent for preparation to Bureau Veritas Mineral Laboratories in Bamako, Mali and assayed at their analytical facilities in Bamako and in Abidjan, Ivory Coast with fire assay with atomic absorption finish and by gravimetric finish for grades above 10gpt Au.

Table 1: Drillhole Highlights at Mankouke South (November 23rd, 2020)

Hole ID

From (m)

To (m)

Interval (m)

gpt Au

Comment

ALL SAP UNLESS NOTED OTHERWISE

DDMAN20-62

9.5

10.5

1

0.73

18.5

19.5

1

0.59

DDMAN20-64

10.5

11.5

1

1.78

47.5

51.5

4

0.80

61.5

72.5

11

1.97

SR starting 68m

70.5

72.5

2

7.83

SR

DDMAN20-65

35.5

47.5

12

1.38

58.5

63.5

5

1.08

DDMAN20-67

25.5

27.5

2

2.25

92.5

93.5

1

0.99

FRESH QFP

DDMAN20-69

57.5

63.5

6

3.34

62.5

63.5

1

16.3

108.5

110.5

2

1.64

FRESH QFP

118.5

123.5

5

0.85

FRESH QFP

DDMAN20-70

35.5

37.5

2

0.84

45.5

48.5

3

0.70

91.5

92.5

1

0.52

95.5

96.5

1

0.94

104.5

106.5

2

1.20

114.5

154.5

40

2.84

121.5

125.5

4

6.23

144.5

152.5

8

7.06

DDMAN20-72

100.5

102.5

2

2.41

112.5

124.5

12

3.52

116.5

119.5

3

9.94

125.5

142.5

7

0.96

151.5

152.5

1

0.62

DDMAN20-73

9.5

20.5

11

0.55

29.5

30.5

1

0.67

DDMAN20-74

80.4

82.4

2

2.19

88.4

93.4

5

2.65

148.4

149.4

1

0.61

SR

DDMAN20-75

48.5

56.5

8

0.64

70.5

73.5

3

1.88

98.5

100.5

2

2.76

120.5

126.5

6

0.60

SR to 125m, then FRESH

DDMAN20-76

135.5

136.5

1

34.0

SR

149.5

150.5

1

0.73

FRESH QFP

DDMAN20-77

10.5

26.5

16

1.03

37.5

38.5

1

2.46

80.5

98.5

18

2.40

SR starting 95m

83.5

85.5

2

9.60

138.3

139.3

1

0.60

FRESH

166.3

183.3

17

3.99

FRESH

168.3

172.3

4

8.43

FRESH

DDMAN20-78

190.3

191.3

1

1.85

FRESH

212.3

213.3

1

0.69

FRESH

DDMAN20-79

4.5

20.5

16

0.65

26.5

30.5

4

3.74

27.5

28.5

1

11.9

39.5

40.5

1

1.73

45.5

92.5

47

2.52

72.5

78.5

6

10.3

102.5

117.5

15

2.23

SR starting 109.5

116.5

117.5

1

13.9

SR

126.5

179.5

53

5.35

128.5

133.5

5

7.78

147.5

148.5

1

16.0

157.5

169.5

12

12.5

193.5

198.5

5

1.79

DDMAN20-80

NSR

DDMAN20-81

46.5

48.5

2

0.69

53.5

59.5

6

13.9

56.5

58.5

2

36.7

88.5

105.5

17

1.91

103.5

104.5

1

16.7

SR

112.5

121.5

9

1.23

120.5

121.5

1

5.60

132.5

144.5

12

2.64

143.5

144.5

1

16.0

150.5

164.5

14

1.29

Table 2: Drillhole ID Mankouke South (November 23rd, 2020)

Hole ID

X Collar

Y Collar

Section

AZM

DIP

DDMAN20-62

262454

1376440

1376440

270

-50

DDMAN20-64

262437

1376349

1376350

270

-50

DDMAN20-65

262501

1376349

1376350

270

-50

DDMAN20-67

262433

1376299

1376300

270

-50

DDMAN20-69

262431

1376250

1376250

270

-50

DDMAN20-70

262592

1375902

1375900

90

-50

DDMAN20-72

262571

1375951

1375950

90

-50

DDMAN20-73

262276

1376390

1376390

90

-50

DDMAN20-74

262538

1375851

1375850

90

-50

DDMAN20-75

262575

1375801

1375800

90

-50

DDMAN20-76

262490

1375900

1375900

90

-50

DDMAN20-77

262802

1376050

1376050

270

-50

DDMAN20-78

262493

1375903

1375900

90

-50

DDMAN20-79

262722

1375867

262700

340

-50

DDMAN20-80

262786

1375800

1375800

270

-50

DDMAN20-81

262795

1375900

1375900

270

-50

Qualified Person (QP) and NI43-101 Disclosure

Greg Isenor, P. Geo., Executive Vice-Chairman for the Company, is the designated Qualified Person for this news release within the meaning of National Instrument 43-101 ("NI 43-101") and has reviewed and verified that the technical information contained herein is accurate and approves of the written disclosure of same.

About Roscan

Roscan Gold Corporation is a Canadian gold exploration company focused on the exploration and acquisition of gold properties in West Africa. The Company has assembled a significant land position of 100%-owned permits in an area of producing gold mines (including B2 Gold's Fekola Mine which lies in a contiguous property to the west of Kandiole), and major gold deposits, located both north and south of its Kandiole Project in West Mali.

For further information, please contact:

Andrew J. Ramcharan, P.Eng
Executive Vice President – Corporate Development & Investor Relations
Tel: (416) 572-2295
Email: aramcharan@Roscan.ca

Greg Isenor, P.Geo
Executive Vice-Chairman
Tel: (902) 221-2329
Email: gpisenor@Roscan.ca

Forward Looking Statements

This news release contains forward-looking information which is not comprised of historical facts. Forward-looking information is characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, and opportunities to differ materially from those expressed or implied by such forward-looking information. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, changes in the state of equity and debt markets, fluctuations in commodity prices, delays in obtaining required regulatory or governmental approvals, and other risks involved in the mineral exploration and development industry, including those risks set out in the Company's management's discussion and analysis as filed under the Company's profile at www.sedar.com. Forward-looking information in this news release is based on the opinions and assumptions of management considered reasonable as of the date hereof, including that all necessary governmental and regulatory approvals will be received as and when expected. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information. The Company disclaims any intention or obligation to update or revise any forward-looking information, other than as required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Roscan Gold Corporation

ReleaseID: 617753

TORONTO, ON / ACCESSWIRE / November 23, 2020 / DigiCrypts Blockchain Solutions Inc. o/a DIGIMAX GLOBAL SOLUTIONS (the "Company" or "DigiMax") (CSE:DIGI) is pleased to announce that in preparation for its December 1 trial launch of its Crypto Trading App, that it is now accepting User applications on the DataNavee website at

https://www.datanavee.com/crypto-currency-trading-tool-registration/

Use of the App will be free for the month of December and will be limited to experienced traders of crypto-currencies so that they can evaluate and provide feedback regarding the usefulness of the App prior to its public launch in January 2021.

A disclosed in its October 29, 2020 Press Release, wholly owned DigiMax subsidiary, DataNavee, has developed an AI-Based predictive trading information platform that has demonstrated an ability for an investor to realize superior rates of return trading crypto currencies such as Bitcoin and Ethereum based on results from trials over the past year.

As with other platforms developed by DataNavee, the program uses AI to sort through reams of data that includes not only the trading history of the currencies, but also both macro- and micro-economic data, world events, and global money flows. Bringing all of this data into one program gives the user an ability to predict small and large changes in pricing direction with a high correlation to actual price moves.

DigiMax is also pleased to announce that investors holding the remaining Convertible Debentures have converted an additional $133,750 of the outstanding Debenture. This leaves only $399,500 of the original $1,030,500 Convertible Debenture value remaining to be converted. As a result of this conversion, DigiMax has issued 2,675,000 common shares and warrants to acquire 1,337,500 shares at $0.05 within the next two years.

Additionally, a total of 800,000 warrants and 750,000 Options were exercised at 5 cents per share resulting in the receipt of $77,500 in cash to the DigiMax treasury.

Finally, the Company announces that Lowell Director has stepped down as a Director effective immediately. Lowell remains as a Registered Trading Representative with DigiMax Capital Corp., the registered Exempt Market Dealer owned by DigiMax.

About DigiMax

DigiMax is based in Toronto and is the first company in the Digital Security space to be both publicly listed (listed on the Canadian Securities Exchange-symbol: DIGI) and own a registered Dealer. Canada, DigiMax Capital Corp is an 'Exempt Market Dealer registered in Ontario.

The Company has a highly qualified management team with extensive experience in global financial and capital markets, combined with a rapidly expanding global presence through collaborative partnerships in the USA, Hong Kong, Indonesia, Malaysia, England, Singapore, Korea and Malta.

Contacts DigiMax:

Chris Carl 
President & CEO 
416-312-9698 
ccarl@digimax-global.com 

Edward Murphy
Chairman
416-720-0456
emurphy@digimax-global.com

Cautionary Note Regarding Forward-looking Statements

NEITHER THE CANADIAN SECURITIES EXCHANGE, NOR THEIR REGULATIONS SERVICES PROVIDERS HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE

This press release contains "forward-looking statements". Forward-looking statements can be identified by words such as: anticipate, intend, plan, goal, seek, believe, project, estimate, expect, strategy, future, likely, may, should, will and similar references to future periods. Examples of forward-looking statements in this press release include, among others, statements we make regarding a second closing.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: shareholders approving the change of name to DigiMax, the adequacy of our cash flow and earnings, the availability of future financing and/or credit, and other conditions which may affect our ability to expand the App Platform described herein, the level of demand and financial performance of the cryptocurrency industry, developments and changes in laws and regulations, including increased regulation of the cryptocurrency industry through legislative action and revised rules and standards applied by the Canadian Securities Administrators, Ontario Securities Commission, and/or other similar regulatory bodies in other jurisdictions, disruptions to our technology network including computer systems, software and cloud data, or other disruptions of our operating systems, structures or equipment, as well as those risk factors discussed or referred to in disclosure documents filed by the Company with the securities regulatory authorities in certain provinces of Canada and available at www.sedar.com.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable securities laws, we undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

SOURCE: DigiMax Global Solutions

ReleaseID: 617936

TORONTO, ON / ACCESSWIRE / November 23, 2020 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT) (OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds ("PDC") and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that the U.S. Food and Drug Administration ("FDA") has granted Theralase® Fast Track Designation ("FTD") for its Phase II Bacillus Calmete Guérin ("BCG")-Unresponsive Non Muscle Invasive Bladder Cancer ("NMIBC") Carcinoma In Situ ("CIS") clinical study ("Study II").

As a Fast Track designee, Theralase® will have access to early and frequent communications with the FDA to discuss Theralase's development plans and ensure timely collection of the appropriate clinical data to support the approval process. The accelerated communication with the FDA potentially allows, TLD-1433, in combination with the TLC-3200 medical laser system ("TLC-3200"), to be the first intravesical patient-specific Ruthenium-based PDC for the treatment of patients with BCG-Unresponsive NMIBC CIS, with or without papillary Ta or T1 tumours. FTD can lead to an Accelerated Approval and Priority Review, if certain criteria are met, which the FDA has previously defined to the Company to represent approximately 20 to 25 patients enrolled and treated, who demonstrate significant safety and efficacy clinical outcomes.

Michael Jewett MD, FRCSC, FACS, Inaugural Farquharson Clinical Research Chair in Oncology, Departments of Surgery (Urology) and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network ("UHN"), stated "By awarding Fast Track Designation to the photosensitizer drug TLD-1433 activated by the laser TLC-3200, currently being assessed in a Phase II clinical study for the treatment of NMIBC, the FDA has recognized Theralase®'s potential to meaningfully improve patient outcomes for this life-threatening disease. This is a significant accomplishment for the Company. This latest milestone complements the clinical development strategy to provide urologists, uro-oncologists and patients with the tools to combat BCG-Unresponsive NMIBC, safely and effectively."

Shawn Shirazi PhD, Chief Executive Officer, Theralase®, stated, "FDA's FTD for our lead drug candidate, TLD-1433, activated by the TLC-3200, is another important milestone for Theralase®, as it can potentially speed the development of this drug-device combination for NMIBC patients. The TLD-1433 – TLC-3200 technology represents a paradigm shift in medical technology and an advanced approach to treat NMIBC. We are excited by the progress the Company has delivered in Study II, as we continue to enroll and successfully treat patients. The Company continues to work towards launching new clinical study sites in Canada and the US with a mandate to enroll and treat all patients for their first Study II treatment in 2021".

About Fast Track Designation

FTD is an FDA process designed to facilitate the development, and expedite the review of, medicines to treat serious conditions and fill unmet medical needs. Filling an unmet need is defined as providing a therapy where none exists or providing a therapy that may be potentially better than available therapies. The FDA created this process to help deliver important new drugs to patients earlier, and it covers a broad range of serious illnesses.

About Study II

Study II utilizes the Therapeutic Dose (0.70 mg/cm2) of TLD-1433, activated by the TLC-3200, and is focused on the enrollment and treatment of approximately 100 BCG-Unresponsive NMIBC CIS patients in up to 20 clinical study sites located in Canada and the US.

Study II has a:

Primary endpoint of efficacy (defined by Complete Response ("CR") at any point in time
Secondary endpoint of duration of CR at 360 days post-initial CR (approximately 450 days post initial Study treatment, assuming CR is achieved at the 90 day assessment)
Tertiary endpoint of safety measured by incidence and severity of Adverse Events ("AEs") grade 4 or higher that do not resolve within 450 days post-initial treatment

The FDA, in its 2018 guidance to industry, stated that, "For single-arm trials of patients with BCG-Unresponsive disease, CR is defined as at least one of the following:

Negative cystoscopy and negative (including atypical) urine cytology
Positive cystoscopy with biopsy-proven benign or low-grade NMIBC and negative cytology
For intravesical therapies without systemic toxicity, negative cystoscopy with malignant urine cytology, if cancer is found in the upper tract or prostatic urethra and random bladder biopsies are negative.

The FDA further states that, "Intravesical instillation does not deliver the investigational drug to the upper tract or prostatic urethra; therefore, the development of disease in these areas cannot be attributed to a lack of activity of the investigational drug. Thus, sponsors can consider patients with new malignant lesions of the upper tract or prostatic urethra, who have received intravesical therapy to have achieved a CR in the primary analysis; however, sponsors should record these lesions and conduct sensitivity analyses in which these patients are not considered to have achieved a CR."1

About Theralase® Technologies Inc.

Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers, bacteria and viruses.

Additional information is available at www.theralase.com and www.sedar.com.

Forward Looking Statement:

This news release contains "forward-looking statements" which reflect the current expectations of the Company's management for future growth, results of operations, performance, business prospects and opportunities. Such statements include, but are not limited to, statements regarding the Company's proposed development plans with respect to Photo Dynamic Compounds and their drug formulations. Wherever possible, words such as "may", "would", "could", "should", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "potential for" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions; including, with respect to the ability of the Company to: adequately fund, secure the requisite regulatory approvals to commence and successfully complete a Phase II NMIBC clinical study in a timely fashion and implement its commercialization plans. Many factors could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For More Information:

1.866.THE.LASE (843-5273)
416-699-LASE (5273)
www.theralase.com

Kristina Hachey
Chief Financial Officer
khachey@theralase.com
416-699-LASE (5273) x 224

1 "BCG-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment – Guidance for Industry" Dated: February 2018

SOURCE: Theralase Technologies Inc.

ReleaseID: 617881

Preliminary First-in-Human Study Results Published in Peer-Reviewed Journal

IRVINE, CA / ACCESSWIRE / November 23, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the Journal of Vascular Surgery Venous and Lymphatic Disorders, published a paper featuring interim results from the VenoValve first-in-human trial. The article entitled "Human Trial Using the Novel Bioprosthetic VenoValve in Patients with Chronic Venous Insufficiency" is published online on the journal's website. This article emanated from a presentation on the VenoValve given at Southern Association of Vascular Surgery, January 8, 2020 conference in Palm Beach, Florida by Dr. Jorge Ulloa, the principal investigator for the study as well as President of Vascular Society of Colombia.

Dr. Marc Glickman, HJLI's Senior Vice President and Chief Medical Officer and co-author of the article stated, "JVS represents the pinnacle of peer-reviewed journals for vascular surgery. The journal focuses on latest and most innovative devices and treatments for vascular disease and is widely read by vascular surgeons and health care professionals. We are thrilled to have the opportunity to inform the medical community about our progress with the VenoValve".

HJLI expects to release additional updated results from the VenoValve first-in-human trial throughout the fourth quarter as additional patients complete the one-year study. The first phase of the Colombian study, during which all 11 patients will have achieved the important one-year milestone, will conclude in December of 2020. Preparations have begun for HJLI to file the IDE application with the U.S. Food and Drug Administration for the VenoValve U.S. Pivotal trial, which the company expects to file in Q1 of 2021.

The VenoValve is a porcine based bioprosthetic device that is implanted in the deep femoral vein of the leg to treat a condition called Chronic Venous Insufficiency ("CVI"). CVI occurs when the valves in the veins of the leg are injured or destroyed, causing blood to flow backwards ("reflux"), and increasing pressure in the veins of the leg ("venous hypertension"). Deep venous CVI is a serious condition, often resulting in debilitating pain, swelling, and open sores (venous ulcers) on the lower leg. The VenoValve has demonstrated the potential to improve reflux, alleviate disease manifestations, reduce pain, promote venous ulcer healing, and significantly improve the quality of the lives of the 8 VenoValve patients that have completed the study to date.

Approximately 2.4 million people in the U.S. suffer from CVI due to reflux in the deep venous system. Estimates indicate that direct medical costs from CVI in the U.S. exceed $38 Billion a year. There are currently no FDA approved devices, or effective treatments for deep venous CVI.

The Journal of Vascular Surgery: Venous and Lymphatic Disorders is the premier international journal of medical, endovascular, and surgical management of venous and lymphatic disorders. An abstract of the article can be accessed here: https://www.jvsvenous.org/article/S2213-333X(20)30636-3/fulltext#secsectitle0010 with public access to the full article soon to follow.

About Hancock Jaffe Laboratories, Inc.
HJLI specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValve® , a porcine based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency; and the CoreoGraft® , a bovine tissue-based off the shelf conduit intended to be used for coronary artery bypass surgery. For more information, please visit HancockJaffe.com.

Cautionary Note on Forward-Looking Statements
This press release and any statements of stockholders, directors, employees, representatives and partners of Hancock Jaffe Laboratories, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results (including, without limitation, the closing of the offering described in this release) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

SOURCE: Hancock Jaffe Laboratories, Inc.

ReleaseID: 617818

VANCOUVER, BC / ACCESSWIRE / November 23, 2020 / HIVE Blockchain Technologies Ltd. (TSX.V:HIVE)(OTCQX:HVBTF)(FSE:HBF) (the "Company" or "HIVE") is excited to announce that it has entered into a non-binding, exclusive memorandum of understanding ("MOU") with GPU.One Holding Inc. ("GPU.One") to expand HIVE's Canadian footprint through the potential purchase of GPU Atlantic Inc. ("GPU Atlantic").

Pursuant to the MOU, HIVE would purchase 100% of the GPU Atlantic shares (the "Proposed Transaction"). The eventual purchase price is dependent on the negotiation of a definitive agreement, including a formal purchase agreement, and the completion of a satisfactory due diligence process.

"We are excited about this opportunity for HIVE to expand our Canadian footprint through the acquisition of this data centre campus which has access to 50 megawatts ("MW") of low-cost green power in Grand Falls, New Brunswick," said Frank Holmes, Interim Executive Chairman of HIVE. Mr. Holmes added, "Further, and important to building our vision, is the GPU.One team of young, skilled and proven data centre professionals with deep high density data centre build out and maintenance experience who will take on executive positions within HIVE's organization."

In connection with this Proposed Transaction, the Company has retained Canaccord Genuity Corp. to act as advisor and assist with due diligence.

About GPU.ONE

GPU.One is one of the industry's premier data centre operators and managers. Winner of Bitmain's "Top 10 Mining Farms in the World", GPU.One is a privately held venture-backed and institution-backed data centre owner and operator. GPU.One has a current capacity of 70 MW, 50 MW of which are presently in full operation utilising renewable hydro-energy in Québec and Atlantic Canada. GPU.One's in-house software is ahead of the competition and provides seamless and remote control of its facilities, HVAC, as well as over each individual server under management.

About GPU Atlantic Inc.

GPU Atlantic Inc. has recently constructed a new and state of the art 50 MW data centre campus located in New Brunswick, Canada. The campus contains GPU.One's own private 50 MW substation along with two data centre facilities. The campus also provides for space, electrical capacity, and materials to continue its pursuit of growth within the existing infrastructure.

About HIVE Blockchain Technologies Ltd.

HIVE Blockchain Technologies Ltd. is a growth oriented, TSX.V-listed company building a bridge from the blockchain sector to traditional capital markets. HIVE owns state-of-the-art green energy-powered data centre facilities in Canada, Sweden, and Iceland which produce newly minted digital currencies like Bitcoin and Ethereum continuously on the cloud. Our deployments provide shareholders with exposure to the operating margins of digital currency mining as well as a portfolio of crypto-coins. This is another key step in building our vision to have a 1,000 petahashes of Bitcoin mining capacity over the next 12 months.

For more information and to register to HIVE's mailing list, please visit www.HIVEblockchain.com. Follow @HIVEblockchain on Twitter and subscribe to HIVE's YouTube channel.

On Behalf of HIVE Blockchain Technologies Ltd.
"Frank Holmes"
Interim Executive Chairman

For further information please contact:
Frank Holmes
Tel: (604) 664-1078

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward-Looking Information

Except for the statements of historical fact, this news release contains "forward-looking information" within the meaning of the applicable Canadian securities legislation that is based on expectations, estimates and projections as at the date of this news release. "Forward-looking information" in this news release includes information about the Proposed Transaction, achievement of aggregate operating hashpower of 1,000 PH/s within the next 12 months, potential further improvements to profitability and efficiency across mining operations, potential for the Company's long-term growth, and the business goals and objectives of the Company.

Factors that could cause actual results to differ materially from those described in such forward-looking information include, but are not limited to, a decrease in Ethereum pricing, volume of transaction activity or generally, the profitability of Ethereum mining; further improvements to profitability and efficiency may not be realized; the Company may not be able to enter into a definitive agreement on terms which are economic or at all or close the Proposed Transaction; the ongoing operation of the digital currency market; the Company's ability to successfully mine digital currency; the Company may not be able to profitably liquidate its current digital currency inventory, or at all; a decline in digital currency prices may have a significant negative impact on the Company's operations; the volatility of digital currency prices; and other related risks as more fully set out in the Filing Statement of the Company dated and other documents disclosed under the Company's filings at www.sedar.com.

The forward-looking information in this news release reflects the current expectations, assumptions and/or beliefs of the Company based on information currently available to the Company. In connection with the forward-looking information contained in this news release, the Company has made assumptions about the current profitability in mining Ethereum (including pricing and volume of current transaction activity); the ability to enter into a definitive agreement and close the Proposed Transaction on terms which are economic; profitable use of the Company's assets going forward; the Company's ability to profitably liquidate its digital currency inventory as required; historical prices of digital currencies and the ability of the Company to mine digital currencies will be consistent with historical prices; and there will be no regulation or law that will prevent the Company from operating its business. The Company has also assumed that no significant events occur outside of the Company's normal course of business. Although the Company believes that the assumptions inherent in the forward-looking information are reasonable, forward-looking information is not a guarantee of future performance and accordingly undue reliance should not be put on such information due to the inherent uncertainty therein.

SOURCE: Hive Blockchain Technologies Ltd

ReleaseID: 617905

Iron Mountain Refrigeration & Equipment offers an ever-expanding selection of commercial and retail refrigeration equipment. The products are sold online with free shipping nationwide.

BRISTOL, WI / ACCESSWIRE / November 23, 2020 / Iron Mountain Refrigeration & Equipment is pleased to announce that their selection of commercial refrigeration equipment continues to grow and expand. The available inventory reflects equipment that is both attractive and durable. The appearance of the equipment is important to customers, employees, and owners as well. An attractive selection of refrigeration equipment reflects pride of ownership and confidence-building for the products placed in the units.

The commercial and industrial refrigeration equipment is top quality commercial grade and is easy and convenient to order. The company has customers in both commercial and residential settings. It offers free shipping nationwide for both, with lift gates and free delivery appointments as required, and no hidden extra charges. Whether the customer is looking for units to further restaurant refrigeration, set up a home bar beer cooler, or showcase a retail product or other, the firm has a selection of equipment to keep goods cool. Additionally, Iron Mountain Refrigeration & Equipment takes great pride in customer care, and will go the extra mile to ensure the satisfaction of all customers.

Whether the business is a bar, pizza kitchen, restaurant, delicatessen, or commercial kitchen, the company has the equipment ready to ship. Some of the equipment includes freezers for restaurant kitchen equipment, counter height back bar coolers, deep well bottle coolers, commercial kitchen refrigerators, glass door refrigerator coolers, refrigerated pizza sandwich prep tables, large or small delicatessen cases, commercial ice makers, glass-front display freezers, dual tap kegerators, Slushie machines and juice dispensers, cake display glass bakery cases, glass frosted bar freezers, and under-counter residential bar refrigerators.

More details are available at https://ironmountainrefrigeration.com/

With the right equipment, clients or customers can be confident that any foods or drinks they buy have been properly refrigerated. The premises' professional and clean appearance is essential, whether they are part of a restaurant, convenience store, gas station, hotel, or any other commercial building. The appearance of the equipment is a crucial part of the feel and look of the entire establishment.

About the Company:

Iron Mountain Refrigeration & Equipment is a family-owned and operated business in Bristol, Wisconsin, offering commercial or industrial refrigeration products.

Media Contact
Iron Mountain Refrigeration & Equipment
Bristol, Wisconsin. USA
(833) 734-8880
Michelle@imref1.com

SOURCE: Iron Mountain Refrigeration & Equipment

ReleaseID: 617938